Biogen adds a late-stage prospect to its growing biosimilar business

Biogen has secured exclusive rights to develop, manufacture and sell an experimental copycat version of Actemra, the blockbuster anti-inflammatory drug which recently came into the spotlight as a promising treatment for COVID-19.